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HYPERTROPHIC CARDIOMYOPATHY
General considerations. Hypertrophic cardiomyopathy
(HCM) is a relatively common form of genetic heart disease
(0.2%; 1:500 in the general population) (1), and the most
common cause of sudden unexpected cardiac death in young
people, including competitive athletes (2). Sudden death
may occur at any age, but is most common in individuals 30
years of age or less. At present, 12 mutant genes (most
encoding sarcomeric proteins) and over 400 specific muta-
tions in these genes have been implicated in the pathogen-
esis of clinically diagnosed HCM (3).
The disease is characterized by heterogeneous presen-
tation and natural history in which the most consistent
diagnostic feature demonstrated by echocardiography is
otherwise unexplained and usually asymmetric hypertro-
phy associated with a non-dilated left ventricle (LV)
(3–5). Clinical diagnosis of HCM is made by recognition
of the disease phenotype with LV hypertrophy (3,4). In
this regard, a maximal LV end-diastolic wall thickness of
15 mm or more (or on occasion, 13 or 14 mm) is the
absolute dimension generally accepted for the clinical
diagnosis of HCM in an adult athlete (in children, 2 or
more standard deviations from the mean relative to body
surface are; z-score of 2 or more); however, any LV wall
thickness (including normal) is theoretically compatible
with the presence of a mutant HCM gene (3,4). Of note,
individuals of virtually any age (but usually less than 14
years old) harboring a HCM-causing mutant gene may
not manifest LV hypertrophy (3,4).
In a disease such as HCM, extrapolation of risk level
from non-athletes to highly trained competitive athletes is
tenuous. This relates to the unstable electrophysiologic
substrate and propensity for potentially lethal ventricular
tachyarrhythmias in HCM, interacting with the physiologic
stresses inherent in athletic training and competition (i.e.,
alterations in blood volume, hydration, and electrolytes).
Furthermore, no single clinical, morphologic, or electro-
physiologic factor has emerged as the reliable predictor of
risk in HCM (3,4). Therefore, because the panel could not
precisely stratify sudden death risk specifically for all athletes
with HCM, the present recommendations for sports eligi-
bility remain conservative and homogeneous for those
athletes within the diverse HCM clinical spectrum.
Given the inability to precisely stratify risk on clinical
grounds in individual young patients with HCM, a broad
recommendation to exclude such individuals from compet-
itive sports will, by definition, deny participation to some
unnecessarily. However, given the frequency with which
HCM is associated with sudden death in young athletes (2),
and recent data showing that athletic activity per se is
associated with higher risk in those with underlying cardio-
vascular abnormalities (6), the present recommendations are
viewed as prudent. That is, the goal is to encompass all
preventable sudden deaths in young persons with HCM,
while acknowledging that other athletes who may not be
destined for sudden death will also be subjected to the same
recommendations.
Preclinical diagnosis. With the availability of preclinical
genetic diagnosis, a relatively small number of youthful
family members have been identified as affected by a
HCM-causing mutant gene solely on the basis of laboratory
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DNA analysis, and in the absence of typical morphologic
(phenotypic) features of the disease (3,4). As family genetic
screening for HCM becomes more widespread, clinicians
may be increasingly faced with the dilemma of making
recommendations regarding sports participation for subjects
who have only preclinical evidence of HCM (i.e., genotype
positive-phenotype negative). Nonetheless, it is likely that
most such individuals are destined to ultimately develop the
HCM phenotype with the attendant possibility of a poten-
tially unstable electrophysiologic milieu. Moreover, the
HCM phenotype (i.e., LV hypertrophy) may develop over
the course of several years (3,4) after initial evaluation, when
competitive sports participation could still be an ongoing
and important lifestyle issue.
Based on these considerations, prudent recommendations
for athletes with preclinical HCM would include, on a 12-
to 18-month basis, in addition to serial two-dimensional
echocardiography: 12-lead ECG and ambulatory Holter
electrocardiogram (ECG), and less frequently cardiac mag-
netic resonance (CMR) imaging and exercise stress testing
to a level similar to that expected in the sport under
consideration (for evaluation of exercise tolerance, blood
pressure, and ventricular tachyarrhythmias). If all of these
parameters continue to be normal, then based on the level of
present knowledge, restriction from competitive athletic
activities is not recommended. Such systematic follow-up of
this subgroup is strongly recommended, particularly if there
is a family history of HCM and sudden cardiac death.
Relevant to these considerations are the prior observa-
tions that abnormalities on 12-lead ECG and preload-
independent measures of diastolic dysfunction with tissue
Doppler ultrasonography may precede the appearance of
LV hypertrophy, providing clues to impeding development
of wall thickening (7–9). Athletes with abnormal 12-lead
ECG and absence of LV hypertrophy on two-dimensional
echocardiogram (particularly if relatives in HCM families)
should be afforded a high index of suspicion for HCM and
undergo CMR imaging to determine whether areas of
segmental hypertrophy undetected by echocardiography are
present in regions of the LV chamber such as anterolateral
free wall or apex (7). However, 12-lead ECG abnormalities
in family members without LV hypertrophy (particularly if
relatively minor or nonspecific) should not per se be re-
garded as evidence of HCM.
Recommendations:
1. Athletes with a probable or unequivocal clinical diag-
nosis of HCM should be excluded from most com-
petitive sports, with the possible exception of those of
low intensity (class IA). This recommendation is
independent of age, gender, and phenotypic appear-
ance, and does not differ for those athletes with or
without symptoms, LV outflow obstruction, or prior
treatment with drugs or major interventions with
surgery, alcohol septal ablation, pacemaker, or im-
plantable defibrillator.
2. Although the clinical significance and natural history
of genotype positive-phenotype negative individuals
remains unresolved, no compelling data are available
at present with which to preclude these patients from
competitive sports, particularly in the absence of
cardiac symptoms or a family history of sudden death.
Given the effectiveness of implantable cardioverter-
defibrillators (ICDs) in preventing sudden death in HCM
(10), clinicians will increasingly be faced with decisions
regarding athletic participation for HCM patients with
ICDs. Although effective for sudden death prevention in
observational studies (10), the unique physiologic milieu
associated with competitive athletic activities, including
intravascular volume and electrolyte disturbances, neurohor-
monal activity, and the potential for myocardial ischemia
make the absolute reliability of ICDs in such settings
unpredictable. Furthermore, there is a possibility for device
malfunction and the risk for traumatic injury to the athlete-
patient (or other competitors) should the ICD discharge
either appropriately or inappropriately. Thus, the placement
of an ICD in an HCM patient does not change the
competitive sports recommendations for this disease (as
previously noted), namely, that restriction from participa-
tion in contact and most non-contact sports is advisable
(11); such individuals may engage only in low-intensity
competitive sports (class IA).
The presence of a free-standing automated external
defibrillator (AED) at sporting events should not be con-
sidered either absolute protection against sudden death, a
prospectively designed treatment strategy for known cardio-
vascular disease, nor a justification for participation in
competitive sports in athletes with previously diagnosed
HCM. Athletes with HCM using drugs such as anabolic
steroids or energy stimulant drinks may in fact increase their
risk of arrhythmias, although definitive data are lacking.
MITRAL VALVE PROLAPSE (MVP)
Mitral valve prolapse (i.e., myxomatous degeneration) is of
particular importance in the evaluation of athletes, given its
relatively high prevalence in the general population (esti-
mated, 2% to 3%) (12–14). The condition is defined by
echocardiography as systolic displacement of one or both
mitral leaflets into the left atrium beyond the plane of the
mitral anulus in the parasternal long-axis view (13). These
patients may be identified by auscultation with a mid-
systolic click and/or murmur of mitral regurgitation. Addi-
tionally, MVP is characterized by a mostly favorable prog-
nosis and low event rate (12–15). In general, the greatest
risks for unfavorable clinical sequelae—which include severe
progressive mitral regurgitation requiring valve surgery,
infective endocarditis, embolic events, atrial and ventricular
tachyarrhythmias, and sudden death appear to be associated
with substantial structural abnormality of the mitral valve
(i.e., “classic” MVP) with diffuse leaflet thickening, elonga-
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tion, and redundancy, and in some cases ruptured chordae
tendineae (12–15).
Sudden cardiac death due to isolated MVP is rare among
young patients, particularly in relation to exercise and/or in
trained athletes (12–16). Such events are probably not more
frequent than in the general population and occur predom-
inantly in patients older than 50 years with severe mitral
regurgitation and/or systolic dysfunction (15).
Some individuals with MVP appear to be part of a
connective tissue phenotypic spectrum with tall, thin habi-
tus, thoracic cage deformity, and joint hypermobility (i.e.,
MASS phenotype), for which there is a risk, albeit low, for
progression to aortic dilatation or sudden death (17).
Recommendations:
1. Athletes with MVP— but without any of the following
features— can engage in all competitive sports:
a. prior syncope, judged probably to be arrhythmo-
genic in origin
b. sustained or repetitive and nonsustained supraven-
tricular tachycardia or frequent and/or complex
ventricular tachyarrhythmias on ambulatory Holter
monitoring
c. severe mitral regurgitation assessed with color-flow
imaging
d. LV systolic dysfunction (ejection fraction less than
50%)
e. prior embolic event
f. family history of MVP-related sudden death
2. Athletes with MVP and any of the aforementioned
disease features can participate in low-intensity com-
petitive sports only (class IA).
Recommendations related to hemodynamic burden sec-
ondary to moderate-severe mitral regurgitation (as assessed
by physical examination and two-dimensional echocardio-
gram and Doppler study) in athletes with MVP appear in
Task Force 3.
MYOCARDITIS
Myocarditis is an inflammatory disease of myocardium and
a cause of sudden death in young athletes (2,18–24). It is
usually of infectious etiology due to a variety of viral agents,
most commonly enterovirus (e.g., Coxsackie virus), adeno-
virus, or parvovirus in young people, but also by drugs and
toxic agents such as cocaine (22–25). Myocarditis evolves
through active, healing, and healed pathologic stages—
characterized progressively by inflammatory cell infiltrates
leading to interstitial edema and focal myocyte necrosis and
replacement fibrosis (20)—which potentially create an elec-
trically unstable substrate for development of ventricular
tachyarrhythmias (2,18,24). In some instances, viral myo-
carditis can culminate in dilated cardiomyopathy with LV
systolic dysfunction, presumably as a consequence of viral-
mediated immunologic damage to the myocardium or
cytoskeletal disruption (22–25).
Myocarditis can be diagnosed by established histopatho-
logic, histochemical, or molecular criteria (20,23–25), but is
challenging to identify clinically. Suspicion may be raised by
chest pain, exertional dyspnea, fatigue, syncope, palpita-
tions, ventricular tachyarrhythmias and conduction abnor-
malities or by acute congestive heart failure associated with
LV dilatation and/or segmental systolic dysfunction, cardio-
genic shock, or ST-T changes on ECG (22,24).
When clinical judgment suggests the presence of myo-
carditis, an endomyocardial biopsy may clarify an otherwise
ambiguous clinical profile. Because of patchy distribution of
inflammatory cells, biopsies are often insensitive and fre-
quently yield false-negative histologic results (20,22,24).
However, the diagnostic yield of histology can be enhanced
by molecular analysis with PCR amplification of the viral
genome (23,25).
Recommendations:
1. Athletes with probable or definite evidence of myo-
carditis should be withdrawn from all competitive
sports and undergo a prudent convalescent period of
about six months following the onset of clinical
manifestations.
2. Athletes may return to training and competition after
this period of time if:
a. LV function, wall motion, and cardiac dimensions
return to normal (based on echocardiographic and/or
radionuclide studies at rest and with exercise)
b. clinically relevant arrhythmias such as frequent
and/or complex repetitive forms of ventricular or
supraventricular ectopic activity are absent on am-
bulatory Holter monitoring and graded exercise
testing
c. serum markers of inflammation and heart failure
have normalized
d. the 12-lead ECG has normalized. Persistence of
relatively minor ECG alterations such as some
ST-T changes are not, per se, the basis for restric-
tion from competition.
MARFAN SYNDROME
Marfan syndrome (and related disorders), caused by more
than 400 individual mutations in the gene encoding
fibrillin-1 (FBN1), is an autosomal dominant disorder of
connective tissue with estimated prevalence of 1:5,000 to
1,10,000 in the general population (26–29). It is character-
ized clinically by a diverse constellation of abnormalities
variable in severity and involving primarily the ocular,
skeletal, and cardiovascular organ systems (28–30). Diag-
nosis is made according to the Gent nosology if major
criteria are present in two organ systems and a third is
involved, or when there is a family history of Marfan
syndrome (28,29). Skeletal abnormalities include arm span-
to-height ratio greater than 1.05, tall stature, arachnodac-
tyly, dolichostenomelia (long, thin limbs), hyperextensibility
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and ligamentous laxity, scoliosis, and chest wall deformity
(pectus excavatum or carinatum), in addition to ectopia
lentis (lens dislocation).
Cardiovascular manifestations that impact on natural
history are: 1) progressive dilatation of the aortic root or
descending aorta, which predisposes to dissection and rup-
ture (30–33); and 2) MVP with associated mitral regurgi-
tation or LV systolic dysfunction, which may occasionally
predispose to ventricular tachyarrhythmias and sudden
death (33). The risk for aortic rupture is usually linked to
marked enlargement of the aorta (transverse dimension
greater than 50 mm), although dissection can occur with a
normal (or near-normal) aortic root dimension (30–36) (A.
DePaepe, personal communication, April 12, 2004).
Weightlifting has been specifically associated with aortic
dissection in athletes with cystic medial necrosis (with or
without systemic hypertension or use of anabolic steroids)
(35,36). The incidence of aortic dissection appears to have
decreased with earlier prophylactic surgical aortic root
reconstruction and beta-blocker therapy (30,32,34).
Ascending aortic root dilatation (and dissection) has also
been associated with congenital bicuspid aortic valve dis-
proportionate to that attributable to abnormal valvular
function (37–41), as well as familial aortic aneurysm and
dissection, independent of Marfan syndrome (41–43).
Recommendations:
1. Athletes with Marfan syndrome can participate in low
and moderate static/low dynamic competitive sports
(classes IA and IIA) if they do not have one or more of
the following:
a. aortic root dilatation (i.e., transverse dimension 40
mm or greater in adults, or more than 2 standard
deviations from the mean for body surface area in
children and adolescents; z-score of 2 or more)
b. moderate-to-severe mitral regurgitation
c. family history of dissection or sudden death in a
Marfan relative
It is recommended, however, that these athletes have
an echocardiographic measurement of aortic root di-
mension repeated every six months, for close surveil-
lance of aortic enlargement.
2. Athletes with unequivocal aortic root dilatation
(transverse dimension 40 mm or greater in adults or
greater than 2 standard deviations beyond the mean
for body surface area in children and adolescents;
z-score of 2 or more) (41,43), prior surgical aortic root
reconstruction, chronic dissection of aorta or other
artery, moderate-to-severe mitral regurgitation, or
family history of dissection or sudden death can
participate only in low-intensity competitive sports
(class IA).
3. Athletes with Marfan syndrome, familial aortic aneu-
rysm or dissection, or congenital bicuspid aortic valve
with any degree of ascending aortic enlargement (as
defined in 1 and 2 above) also should not participate
in sports that involve the potential for bodily colli-
sion.
4. Recommendations related to aortic regurgitation are
the same as those in Task Force 3.
These recommendations are offered independent of
whether beta-blockers are administered to mitigate aortic
root enlargement.
EHLERS-DANLOS SYNDROME
The vascular form of Ehlers-Danlos syndrome carries a
substantial risk of rupture of the aorta and its major
branches (28). This is a rare autosomal dominant disorder,
caused by a defect in type III collagen, encoded by the
COL3A1 gene. Patients have variable joint hypermobility,
susceptibility to bruising, difficult wound healing, and often
prematurely aged appearance.
Recommendation:
1. Individuals with the vascular form of Ehlers-Danlos
syndrome should not engage in any competitive
athletic activity.
ARRHYTHMOGENIC RIGHT VENTRICULAR
CARDIOMYOPATHY (ARVC)
Cited as a major cause of sudden death in young people and
athletes (44–46), particularly in the northeastern (Veneto)
region of Italy (45) but seemingly less common in the U.S
(2,18), ARVC is characterized by a broad phenotypic
spectrum and characteristically by loss of myocytes in the
right ventricular myocardium with fatty or fibro-fatty re-
placement resulting in segmental or diffuse wall thinning. It
is frequently associated with myocarditis (44,45,47). Clini-
cal diagnosis is challenging, but relies largely on familial
occurrence, ventricular tachyarrhythmias (particularly ven-
tricular tachycardia of right ventricular origin elicited by
exercise), T-wave inversion in precordial leads V1 through
V3 and epsilon waves on ECG, or right ventricular dilata-
tion and/or segmental wall motion abnormalities, aneurysm
formation, and fatty deposition in the right ventricular wall
identified with echocardiography, multi-slice computed to-
mography, or cardiac magnetic resonance imaging.
Recommendation:
1. Athletes with probable or definite diagnosis of
ARVC should be excluded from most competitive
sports, with the possible exception of those of low
intensity (class IA).
OTHER MYOCARDIAL DISEASES
A number of other uncommon diseases of the myocardium
deserve consideration as potential causes of sudden death in
athletes. These include dilated cardiomyopathy (due to a
variety of etiologies including genetic); primary non-
hypertrophied restrictive cardiomyopathy, systemic infiltra-
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tive diseases with secondary cardiac involvement such as
sarcoidosis, and also isolated non-compaction of LV myo-
cardium with or without systolic dysfunction (48,49). Few
data are presently available regarding the relative risks of
athletic training and competition in athletes with the
aforementioned myocardial diseases.
Recommendation:
1. Until more information is available in this regard, it
is most prudent to exclude athletes with these dis-
eases from most competitive sports, with the possible
exception of those of low intensity (class IA) in
selected cases.
PERICARDITIS
Recommendation:
1. Athletes with pericarditis, regardless of etiology,
should not participate in competitive sports during
the acute phase. Such athletes can return to full
activity when there is no longer evidence of active
disease, including effusion by echocardiography, and
when serum markers of inflammation have normal-
ized. For pericarditis associated with evidence of
myocardial involvement, eligibility recommendations
should also be based on the course of myocarditis.
Chronic pericardial disease that results in constric-
tion disqualifies one from all competitive sports.
doi:10.1016/j.jacc.2005.02.011
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